Stockreport

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Verrica Pharmaceuticals Inc.  (VRCA) 
Last verrica pharmaceuticals inc. earnings: 3/13 07:00 am Check Earnings Report
PDF – Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a mu [Read more]